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Abstract
Background: Children with type 1 diabetes (DM1) often use three daily (TID) injections with intermediate acting
insulin at breakfast and bedtime, and rapid acting insulin at breakfast and dinner. Substituting the evening
intermediate acting insulin with a long acting insulin analogue (LAIA) at dinner in a twice daily (BID) injection
regimen may be as effective as a TID regimen. The objective of this pilot study was to compare HbA1c in children
with DM1 using a BID regimen with a LAIA at dinner (intervention) to those using a standard TID regimen (control)
over 6 months.
Methods: Randomized controlled trial with main outcome measure being HbA1c at 0, 3 and 6 months. Secondary
outcomes were frequency of adverse events (hypoglycemia, diabetic ketoacidosis, weight gain) and scores on the
Diabetes Quality of Life Measure for Youth (DQOLY).
Results: 18 subjects (10 control, 8 intervention). Mean years (standard deviations) for control and intervention
respectively were: age at diagnosis of DM1 6.31 (2.91) vs 7.76 (3.22), duration of DM1 5.96 (4.95) vs 3.76 (3.37). No
significant differences were seen in the mean HbA1c between control and intervention at 0 months [8.48(0.86) vs
8.57(1.13)], 3 months [8.47(0.50) vs 7.99(0.61)], or 6 months [8.42(0.63) vs 8.30(0.76)]. No significant differences were
found between groups for frequency of adverse events or DQOLY.
Conclusions: In this pilot study, incorporating LAIA in a BID regimen did not cause deterioration in HbA1c or
increases in adverse events; suggesting that this may be a viable option for families where a more simplified
insulin regimen would be beneficial and compliance may be improved.
Trial registration: ClinicalTrials.gov: NCT00522210
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Background
Children with type 1 diabetes (DM1) require multiple
daily injections of insulin to maintain good glycemic
control. The Diabetes Control and Complications Trial
(DCCT) has shown that intensive insulin treatment
using at least three times daily (TID) injections achieves
superior blood glucose control with decreased risk of
long term complications than conventional insulin treat-
ment using once daily or twiced a i l y( B I D )i n j e c t i o n s
[1,2]. However, this study was done when long acting
insulin analogues (LAIA) were not available which lim-
ited the types of insulin regimens and there are limited
randomized controlled trials assessing analogue insulins
in children. Multiple daily injection regimens are not
consistently superior in children and other factors
including patient support and team cohesion play large
roles in glycemic control [3]. Many patients find it diffi-
cult to adhere to TID injections since it is an invasive
and painful therapy, which results in frequent insulin
omission. By replacing bedtime intermediate acting insu-
lin with a LAIA at dinner, this would allow children
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a BID insulin injection regimen.
The pharmacokinetic properties of the LAIA, detemir,
have some potential benefits in the treatment of chil-
dren with DM1 [4-8]. The longer duration of action
would allow this long acting insulin analogue to be
incorporated into a BID insulin regimen that could
potentially offer equivalent glycemic control to a TID
injection regimen. Intermediate and rapid acting insulin
could still be given in the morning to avoid a lunchtime
injection, while rapid acting and long acting insulin
could be given at dinner to cover for the meal plus the
background insulin required until the morning. There-
f o r e ,c h i l d r e no n l yn e e dt ot a k ei n s u l i nt w i c ead a y ,
which may result in greater compliance and improved
quality of life. Satisfaction with diabetes treatment may
also be improved because of more predictable glycemic
control and less frequent adverse events. The risk of
hypoglycemia may be decreased with detemir [4],
because of the flat and protracted pharmacodynamic
profile compared to the peak in insulin activity seen
with intermediate acting insulins. Less frequent episodes
of hypoglycemia may also result in less weight gain that
can be seen in intensive insulin therapy.
The primary objective of this pilot, randomized con-
trolled trial is to compare the glycemic control as mea-
sured by HbA1c in children with DM1 treated with a
BID regimen of insulin using a LAIA overnight versus a
TID insulin injection regimen with intermediate acting
insulin. Secondary objectives included assessing the
satisfaction with treatment of diabetes in each group
using the Diabetes Quality of Life Measure for Youths
(DQOLY) and determining the frequency of adverse
events (severe hypoglycemia, nocturnal hypoglycemia,
mild hypoglycemia, diabetic ketoacidosis, and change in
body mass index (BMI)).
Methods
Study Design
The study was an open-labelled, randomized controlled
trial design with two groups: control group (TID) and
intervention group (BID). The trial was registered at
ClinicalTrials.gov Identifier: NCT00522210.
Subjects
Subjects were recruited from children with DM1 cur-
rently being followed at the Alberta Children’s Hospital
(Calgary, Alberta, Canada). Inclusion criteria were: chil-
dren aged 6-17 years old, diagnosed with DM1 for at
least 1 year and currently being treated with a TID regi-
men of insulin with rapid acting insulin and intermediate
acting insulin. Exclusion criteria were: HbA1c ≥ 10% at
enrolment, chronic underlying medical conditions that
could affect glycemic control (examples: uncontrolled
hypothyroidism, hyperthyroidism, celiac disease, etc.),
current participants of other clinical trials, language or
psychosocial barrier preventing the family from complet-
ing the study.
Protocol
A sample of size of 65 subjects per group was initially
calculated based on an estimated baseline HbA1c of
8.4% (SD 1.3%) in each group, a clinically acceptable dif-
f e r e n c eo f1 0 %( a b s o l u t ed i f f e r e n c eo f0 . 8 4 ) ,ap o w e ro f
90%, and a dropout rate of 20%. Therefore, if one
assumed no drop-outs a sample size of 52 patients per
arm would have been sufficient.
Subjects were randomized into the control group or
intervention group using a computer generated rando-
mization sequence (the sequence was generated in
blocks to keep groups as balanced as possible and to
help ensure allocation concealment). Subjects were stra-
tified by age groups (6 to 10 years, and greater than 10
years old). Given the nature of the intervention, it was
not possible to blind patients, their parents, and care-
givers to the treatment allocation.
In the control group (ie. the TID regimen), subjects
were asked to continue on their usual insulin regimen
(intermediate acting insulin and rapid acting analogue at
breakfast, rapid acting analogue at dinner and inter-
mediate acting insulin at bedtime). In the intervention
group (ie. the BID regimen), the subjects’ usual bedtime
dose of intermediate acting insulin was discontinued
and replaced with a dose of insulin detemir at dinner
time. The intermediate acting insulin used was neutral
protamine hagedorn (either Novolin NPH or Humulin
N depending on what the patient was currently using).
The rapid acting analogues used were lispro insulin
(Humalog) or aspart insulin (Novorapid) depending on
what the patient was currently using. The detemir was
not mixed with the rapid acting insulin and was given
as a separate injection. The dose of detemir was
approximately 50% of the total daily dose of insulin,
with the remaining 50% being comprised of the subject’s
breakfast dose of intermediate acting insulin and rapid
acting analogue and dinner rapid acting analogue. A
run-in period of 1 month, with a minimum of a weekly
phone contact, was used to facilitate the change in insu-
lin regimen and dose finding for the intervention group
and to optimize insulin doses in the control group. No
changes were made to the subjects’ usual diet and exer-
cise routines.
Throughout the study, monthly phone contact for
insulin adjustments was done for both groups. In addi-
tion, subjects were assessed in clinic at baseline, 3
months and 6 months (Figure 1). This included height,
weight, HbA1c, current insulin doses, episodes of severe
hypoglycemia (glucose less than 4 mmol/L associated
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coma), reported nocturnal hypoglycemia, mild hypogly-
cemia (glucose less than 4 mmol/L where the patient is
able to self treat) and diabetic ketoacidosis (hyperglyce-
mia and ketonuria associated with a pH < 7.3 and/or
bicarbonate level < 15 mmol/l).
The Diabetes Quality of Life Measure for Youths
(DQOLY) was administered at baseline and again at 6
months. This questionnaire was initially used by the
DCCT group and was later revised by Ingersoll et al [9].
It has been validated in youths aged 10-21 years. This
instrument has three Likert scales including a 17 item
diabetes life satisfaction scale (range of scores 17-85), 23
i t e md i s e a s ei m p a c ts c a l e( r a n g eo fs c o r e s2 3 - 1 1 5 ) ,a n d
an 11 item disease related worries scale (range of scores
11-55) [9]. In this study, reverse scores were recorded
for the impact and worries scales so that a higher score
indicated a better quality of life. For the satisfaction
scale, a higher score indicates higher satisfaction.
Data Analysis
Baseline demographic and clinical variables are pre-
sented as means with standard deviations (SD) for
numerical variables and as proportions for categorical
variables. The 95% confidence interval for the difference
between groups is presented too. At each time point,
HbA1c between the two groups was compared using a
two sample t-test and confidence interval for the differ-
ence is provided to help assess non-inferiority. The true
expected difference in HbA1c between the control and
treatment group was taken to be zero. Based on pre-
vious follow up data from the ACH Diabetes Clinic, the
mean HbA1C is estimated at 8.4% with a standard
deviation of 1.3 for each group. A 10% relative differ-
ence was considered a clinically acceptable difference.
Therefore, the non-inferiority margin was set at 0.84.
Ethical approval
The protocol, including subject information, informed
consent, recruitment procedure, interventions and data
collection has been approved by the Conjoint Health
Research Ethics Board of the Faculty of Medicine, Uni-
versity of Calgary (Calgary, Alberta, Canada) in accor-
dance with the Declaration of Helsinki and Tri-Council
Guidelines.
Results
Table 1 shows the enrolment characteristics of the sub-
jects. There were no significant differences between the
groups at baseline. In total, 18 subjects were enrolled
(10 control, 8 intervention). The mean age at diagnosis
of DM1 was 6.31 years (SD 2.91) for control and 7.76
years (SD 3.22) for intervention. The mean duration of
DM1 was 5.96 years (SD 4.95) for control and 3.76
years (SD 3.37) for intervention.
There were no significant differences in the mean
HbA1c between control and intervention groups at 0
months [8.48 (SD 0.86) vs 8.57 (SD 1.13)], 3 months
Control
Group
Intervention
Group 6 months 3 months 0 months
Clinic Visit 
-HbA1c
-DQOLY
-Height & 
weight 
-Insulin
adjustment
Clinic Visit 
-HbA1c
-DQOLY
-Height & 
weight 
-Insulin
adjustment
-Adverse
events
review 
Clinic Visit 
-HbA1c
-Height & 
weight 
-Insulin
adjustment
-Adverse
events review 
Phone
-Insulin
adjustment
Phone
-Insulin
adjustment
Phone
-Insulin
adjustment
1 month  2 months  4 months  5 months 
1 month Run-In 
Period
-weekly insulin 
adjustment
BID regimen: Breakfast: intermediate insulin and rapid acting analogue 
                        Supper: detemir and rapid acting analogue 
Standard TID regimen: Breakfast: intermediate insulin and rapid acting analogue 
                                         Supper: rapid acting analogue 
                                         Bedtime: intermediate insulin 
Phone
-Insulin
adjustment
Figure 1 Study design and subject follow up.
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Page 3 of 7[8.47 (SD 0.50) vs 7.99 (SD 0.61)], or 6 months [8.42
(SD 0.63) vs 8.30 (SD 0.76)] (Table 2). Adverse events,
such as DKA and reported hypoglycemic episodes, were
similar in frequency in the control and intervention
groups. There were no significant differences in body
mass index or quality of life scales between groups
(Table 2). The width of the confidence intervals for each
of the outcome measures was large, likely due to the
Table 1 Enrolment characteristics of subjects.
Characteristic Control (TID)
N=1 0
Intervention
(BID)
N=8
Difference between groups
(95% confidence interval for the
difference)
Gender
(Female/Male)
4/6
(40% female)
4/4
(50% female)
10%
(-50.02% - 33.36%)
Age groups
(children < 10 years old/children ≥ 10 years old)
3/7
(30% children < 10 years old)
3/5
(37.5% children
< 10 years old)
7.5%
(-47.08% - 33.74%)
Age at study enrolment
(years)
12.26 (3.40) 11.52 (2.08) -0.74
(-3.52 - 2.03)
Age at type 1 diabetes diagnosis
(years)
6.31 (2.91) 7.76 (3.22) 1.45
(-1.68 - 4.58)
Duration of diabetes
(years)
5.96 (4.95) 3.76 (3.37) -2.20
(-6.37 - 1.98)
Last HbA1c prior to enrolment
(%)
8.54 (0.70) 8.70 (0.58) 0.16
(-0.48 - 0.80)
Insulin dose
(units/kg/day)
1.02 (0.40) 0.94 (0.24) -0.08
(-0.41 - 0.25)
Body Mass Index
(kg/m
2)
20.62 (4.07) 20.99 (3.60) 0.38
(-3.46 - 4.22)
No significant differences were found between the groups at baseline. Table shows Number (%) or Mean (Standard deviation). Difference is for intervention
minus control.
Table 2 Results
Baseline 3 Months 6 Months
Control Intervention Difference
(95%
confidence
interval)
Control Intervention Difference
(95%
confidence
interval)
Control Intervention Difference
(95%
confidence
interval)
HbA1c % 8.48
(0.86)
8.57
(1.13)
0.095
(-0.95 - 1.14)
8.47
(0.50)
7.99
(0.61)
-0.48
(-1.06 - 0.095)
8.42
(0.63)
8.30
(0.76)
-0.12
(-0.84 - 0.60)
Body Mass Index (kg/m2) 20.62
(4.07)
20.99
(3.60)
0.38
(-3.46 - 4.22)
21.81
(6.40)
22.21
(3.48)
0.39
(-4.67 - 5.46)
21.04
(3.87)
21.75
(3.58)
0.71
(-3.03 - 4.45)
DKA (episodes in last 3
months)
00 0 00 0 00 0
Severe Hypoglycemia
(episodes in last 3
months)
0.10
(0.32)
0 -0.10
(-0.33 - 0.13)
0.30
(0.67)
0 -0.30
(-0.78 - 0.18)
0.1
(0.32)
0 -0.10
(-0.33 - 0.13)
Mild/Moderate
Hypoglycemia
#/week
2.11
(1.40)
2.16
(1.65)
0.046
(-1.53 - 1.62)
2.17
(1.76)
1.87
(1.34)
-0.30
(-1.85 - 1.25)
2.12
(1.31)
2.54
(1.36)
0.41
(-0.94 - 1.77)
Nocturnal
Hypoglycemia
#/week
0.15
(0.34)
0.62
(1.03)
0.47
(-0.39 - 1.34)
0.12
(0.32)
0.72
(0.91)
0.59
(-0.18 - 1.36)
0.26
(0.57)
0.50
(0.72)
0.24
(-0.43 - 0.91)
QOL
Impact
83.78
(7.38)
90.37
(8.14)
6.60
(-1.50 - 14.70)
—— — 83.70
(17.57)
91.00
(8.45)
7.30
(-6.28 - 20.88)
QOL
Worries
41.62
(6.30)
42.00
(5.76)
0.37
(-6.10 - 6.85)
—— — 37.90
(8.55)
39.37
(7.29)
1.47
(-6.45 - 9.40)
QOL
Satisfaction
67.33
(8.37)
67.00
(10.42)
-0.33
(-10.28 - 9.61)
—— — 65.00
(12.62)
72.50
(8.37)
7.50
(-3.06 - 18.06)
Comparison of glycemic control, adverse events and quality of life scores between the control and intervention groups. No significant differences were detected
between the groups at baseline, 3 months or 6 months. Dashed line indicates data was not collected at that time point. Control (TID) N = 10. Intervention (BID)
N = 8. Difference is for intervention minus control. Table shows Mean (Standard Deviation).
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intervention was non-inferior when compared to the
control group.
Discussion
Currently, a standard TID injection regimen with inter-
mediate acting insulin at breakfast and bedtime, and
rapid acting insulin at breakfast and dinner is often used
in children. Families that opt for more intensive therapy
can choose a continuous subcutaneous insulin infusion
or a basal bolus regimen. However, these regimens are
costly and require a significant amount of skill and
effort from the family. In addition, patient compliance
with multiple invasive and painful injections can be an
issue when using multiple injections. Another challenge
with exogenous insulin administration is hypoglycemia.
While the results of the DCCT clearly demonstrated the
importance of maintaining a near normal glucose level,
the major adverse event reported in the intensive insulin
treated subset of patients aged 13-17 years was a nearly
three fold increase in severe hypoglycemic events [1,2].
The development of new LAIA offers the opportunity to
simplify insulin regimens while achieving similar glyce-
mic control.
Detemir is a LAIA that has prolonged insulin absorp-
tion with less intra-patient variability in peak insulin
activity as well as very minimal peak activity, in compar-
ison with intermediate acting insulin [10,11]. The phar-
macokinetic properties of detemir have been studied in
patients with DM1 using a euglycemic glucose clamp
technique [5,12]. In comparison to neutral protamine
hagedorn (NPH) insulin, detemir resulted in a more
stable serum concentration of insulin without the peak
seen in NPH [5,12]. In addition, there were less fluctua-
tions in the glucose infusion rates required with detemir
in steady state compared to NPH in steady state [5,12].
Detemir has been shown to have a consistent pharmaco-
kinetic profile in children, adolescents, and adults with
DM1[7,8].
Recently, a retrospective study by Cengiz et al [13]
analyzed the same BID regimen (NPH and rapid acting
insulin analogue at breakfast with insulin detemir and
rapid acting insulin analogue at dinner) in children with
new onset DM1 as an option prior to initiation of insu-
lin pump therapy. They found that by 12 months after
d i a g n o s i so fD M 1 ,4 9o ft h ep a t i e n t sh a dc h a n g e dt o
pump therapy with a median HbA1c of 6.9% while 59
remained on the BID injection regimen with a median
HbA1c of 7.2% [13]. The authors concluded that this
BID regimen was effective in children with new onset
diabetes and had similar glycemic control [13]. The
findings of this retrospective study are consistent with
our results, as we also did not find a difference in glyce-
mic control for patients on TID versus the BID regimen.
In contrast to Cengiz et al’s study [13], our randomized
control trial was aimed at assessing the effectiveness of
a BID regimen in children with DM1 greater than 12
months as an option for families where intensive dia-
betes therapy was not feasible and improved quality of
life could be achieved by simplifying the diabetes
regimen.
HbA1c changes when using insulin detemir has been
studied in children and adolescents with conflicting
results [14-17]. Braun et al [16] reported improved
HbA1c and fewer severe hypoglycemic episodes in a
chart review study of children who were switched from
evening NPH insulin to detemir. Interestingly, in this
study a subset of children under 12 years of age were
treated with a BID regimen and showed an improve-
ment in HbA1c from 8.3% to 7.6% after changing from
evening NPH to detemir [16]. Dundar et al [14]
reported an improvement in HbA1c in children who
changed from a basal bolus regimen with NPH to either
glargine or detemir. This study was limited by the fact
that it was retrospective and was small with only 15
patients in the detemir treated group [14]. In a large,
prospective, 26 week, randomized study of 347 children,
Robertson et al [15] reported no difference in HbA1c in
children changed to basal bolus therapy with either
NPH or detemir compared to pre-basal bolus therapy.
Although HbA1c was not better in the detemir group,
the risk of nocturnal hypoglycemia was 26% lower [15].
Kurtoglu et al [17] retrospectively assessed children that
were initially on basal bolus regimens with NPH or glar-
gine then switched to detemir. After 12 weeks of using
detemir, HbA1c was improved and the frequency of
hypoglycemic episodes was decreased [17]. Although we
did not see a similar improvement in HbA1c in our
patients using detemir, these studies examined detemir
in basal bolus regimens rather than the BID regimen
used in our study. It is also reassuring that our study
did not find a worsening of glycemic control despite
simplifying the insulin regimen.
Hypoglycemia can be a side effect of intensive insulin
therapy. Several studies have demonstrated that detemir
is associated with a decreased frequency of hypoglyce-
mia since it does not have a peak activity [4,18]. In a
randomized, open, cross-over trial [18], detemir has
been compared to NPH insulin in a basal bolus regimen
in adults with DM1 and has been found to be as effec-
tive as NPH in maintaining glycemic control. Fewer
patients experienced hypoglycemia with detemir com-
pared to NPH [18]. Vague et al [4] compared detemir
and NPH in 448 adult patients with DM1 in a basal-
bolus regimen using twice daily detemir or NPH for
basal coverage and rapid acting insulin with each meal.
In their detemir group, more predictable glycemic con-
trol was seen during night-time plasma glucose
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reduction in the frequency of hypoglycemia as well as
weight gain was also seen in their detemir group [4].
Interestingly, there was no difference in the HbA1c
between the two groups after 6 months [4]. In our
study, no differences in reported episodes of hypoglyce-
mia were seen between groups.
Weight gain can be a concern when children are on
intensified insulin regimens or have frequent hypoglyce-
mia. Home et al [6] conducted a 16 week, randomized
control trial of 408 patients with type 1 diabetes. HbA1c
improved by 0.18% in the group using insulin detemir
as the basal insulin compared to NPH insulin [6]. In
addition, there was a decreased frequency of hypoglyce-
mia and no weight gain in the group using insulin dete-
mir compared to the NPH group which did have some
weight gain [6]. Although the insulin regimen used in
our study was not a basal bolus one, we did not find
any significant changes in BMI between the groups.
Diabetic ketoacidosis (DKA) was not seen in either the
control or intervention group. This is not necessarily
surprising given the short duration of this study and
small sample size. Karges et al [19], compared the inci-
dence of DKA in a cohort of 10 682 children and ado-
lescents with DM1 being treated with either NPH
insulin or a LAIA. They found that the incidence of
DKA was significantly higher in patients using glargine
or detemir compared to those using NPH [19]. How-
ever, all of the patients studied were on at least three or
more insulin injections per day while our patients using
detemir were on a BID regimen.
Quality of life measures were not significantly different
between the two groups using the DQOLY. A limitation
of using the DQOLY was that this questionnaire has
only been validated in youths aged 10-21 years [9]. Our
study included children aged 6 years and older. How-
ever, only 1 subject was 7 years old and 5 subjects were
8 to 9 years old at enrolment and the DQOLY was the
most practical and accessible measure to use at the time
of this study.
At the time the study was conducted, it was recom-
mended that families could continue mixing the inter-
mediate insulin and rapid insulin analogue in one
syringe in the morning. However, at supper time the
LAIA and rapid insulin were to be given in two separate
injections. Recently, Nguyen et al [20] published a study
of 14 children with type 1 diabetes who underwent con-
tinuous glucose monitoring and found that mixing insu-
lin detemir with aspart had equivalent effects on blood
glucose when compared with giving them as separate
injections. The ability to mix insulin detemir with aspart
at supper time would again simplify the regimen for
families and potentially have a greater impact on satis-
faction and compliance.
A significant limitation of this study is the small sam-
ple size. Interestingly, recruitment was difficult for this
study. Once families received a description of the alter-
nate BID insulin regimen compared to the traditional
TID regimen, many did not want to risk being rando-
mized to the control group. The theoretical benefits of
decreased nocturnal hypoglycemia and twice daily insu-
lin injection times was very attractive to families; parti-
cularly those that struggle with compliance.
Conclusions
The results of this pilot study demonstrate that using a
BID insulin regimen incorporating a LAIA allows for
maintenance of glycemic control despite a less intensive
injection regimen. Ideally, a basal bolus regimen with
multiple daily injections or an insulin pump would
mimic physiologic insulin secretion most closely, but
practically this is often difficult to achieve in young chil-
dren who are dependent on a responsible adult to be
available for injections.
Simplifying to BID insulin regimens incorporating
L A I Am a yb ep o s s i b l ew i t hn oi n c r e a s ei na d v e r s e
events and comparable HbA1c compared to standard
TID regimens used in children, although larger clinical
studies would be required to confirm this finding.
Although no significant improvements were seen in
DQOLY and nocturnal hypoglycemia, it is important
that HbA1c remained stable, and suggests that this regi-
men is a viable option for families.
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